Dergiler / Turkish Journal of Hematology / 2018 / Cilt: 35 - Sayı: 2

Association of Interleukin-2-330T/G and Interleukin-10-1082A/G Genetic Polymorphisms with B-Cell Non-Hodgkin Lymphoma in a Cohort of Egyptians

Bir Mısırlı Hasta Kohortunda İnterlökin-2-330T/G ve İnterlökin-10-1082A/G Genetik Polimorfizmlerinin B-Hücreli Hodgkin Dışı Lenfoma ile İlişkisi

Sayfa
99–108
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Moreover, IL-10-1082A/G is not a molecular susceptibility marker for B-NHL in Egyptians.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Polymorphisms in the interleukin (IL)-2 and IL-10 genes are known to be associated with susceptibility to different immune-dysregulated disorders and cancers such as non-Hodgkin lymphoma (NHL).
📊
Temel Bulgular & Veri:To explore the possible association between IL-2-330T/G and IL-10-1082A/G single-nucleotide polymorphisms and the susceptibility to B-cell NHL (B-NHL) in Egyptians, we conducted a case-control study.Materials and Methods: Genotyping of the studied genetic variations was done for 100 B-NHL patients as well as 100 age- and sex-matched healthy controls.Results: The IL-2 variant allele occurred at a significantly higher rate in patients than controls and was associated with susceptibility to B-NHL [odds ratio (OR): 1.91, 95% confidence interval (CI): 1.28-2.85].
💡
Sonuç & Katkı:Moreover, IL-10-1082A/G is not a molecular susceptibility marker for B-NHL in Egyptians.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: Polymorphisms in the interleukin (IL)-2 and IL-10 genes are known to be associated with susceptibility to different immune-dysregulated disorders and cancers such as non-Hodgkin lymphoma (NHL). To explore the possible association between IL-2-330T/G and IL-10-1082A/G single-nucleotide polymorphisms and the susceptibility to B-cell NHL (B-NHL) in Egyptians, we conducted a case-control study.Materials and Methods: Genotyping of the studied genetic variations was done for 100 B-NHL patients as well as 100 age- and sex-matched healthy controls.Results: The IL-2 variant allele occurred at a significantly higher rate in patients than controls and was associated with susceptibility to B-NHL [odds ratio (OR): 1.91, 95% confidence interval (CI): 1.28-2.85]. It was also associated with advanced performance status score. IL-2 polymorphism conferred an almost threefold increased risk of diffuse large B-cell lymphoma (OR: 2.64, 95% CI: 1.35-5.15) and a fourfold increased risk of indolent subtypes (OR: 4.34, 95% CI: 1.20-15.7). The distribution of IL-10-1082A/G genotypes in our patients was close to that of the controls. Co-inheritance of the variant genotypes of IL-2 and the common genotype of IL-10 conferred an almost sixfold increased risk (OR: 5.75, 95% CI: 1.39-23.72), while co-inheritance of the variant genotypes of IL-2 and IL-10 conferred fivefold increased risk of B-NHL (OR: 5.43, 95% CI: 1.44-20.45). The variant genotypes of IL-2-330T/G and IL-10-1082A/G had no effect on the disease-free survival of B-NHL patients.Conclusion: The present study highlights the possible involvement of the IL-2-330T/G genetic polymorphism in the susceptibility to B-NHL in Egypt, especially indolent subtypes. Moreover, IL-10-1082A/G is not a molecular susceptibility marker for B-NHL in Egyptians.

Abstract

Amaç: İnterlökin (IL)-2 ve IL-10 genlerindeki polimorfizmlerin değişik immün bozukluklar ve Hodgkin dışı lenfoma (HDL) gibi kanserlere duyarlılık ile ilişkili olduğu bilinmektedir. Mısırlılardaki IL-2-330T/G ve IL-10-1082A/G tek nükleotid polimorfizmleri ile B hücreli HDL’ye (B-HDL) duyarlılık arasındaki olası ilişkinin araştırılması için bir olgu-kontrol çalışması yapılmıştır. Gereç ve Yöntemler: Bahsedilen genetik varyasyonlar için, 100 B-HDL hastası ve yaş ile cinsiyet uyumlu 100 sağlıklı kontrole genotipleme yapıldı. Bulgular: IL-2 varyant alleli hastalarda kontrollere göre anlamlı olarak daha yüksekti ve B-HDL duyarlılığı ile ilişkili bulundu [olasılık oranı (OO): 1,91, %95 güven aralığı (GA): 1,28-2,85). Ayrıca bunun ileri performans skoru ile de ilişkili olduğu görüldü. IL-2 polimorfizminin diffüz büyük B hücreli lenfoma için yaklaşık üç kat (OO: 2,64; %95 GA: 1,35-5,15) ve yavaş seyirli (indolan) alt tiplerde dört kat artış doğurmaktaydı (OO: 4,34, %95 GA: 1,20-15,7). IL-10-1082A/G genotiplerinin dağılımı hastalar ve kontrollerde benzerdi. IL-2 varyant genotipleri ile IL-10’un sık rastlanan genotiplerinin eş kalıtımı yaklaşık altı kat artmış risk (OO: 5,75, %95 GA: 1,39-23,72) yaratmaktayken, IL-2 ve IL-10 varyant genotiplerinin eş kalıtımı B-HDL riskinde beş kat artışa (OO: 5,43, %95 GA: 1,44-20,45) neden olmaktaydı. IL-2-330T/G ve IL-10-1082A/G variant genotiplerinin B-HDL hastalarında hastalıksız sağkalım üzerine etkisi yoktu. Sonuç: Bu çalışma Mısır’da, IL-2-330T/G genetik polimorfizmlerinin özellikle yavaş seyirli B-HDL’ye yatkınlık ile olası ilişkisini vurgulamaktadır. Ayrıca Mısırlılarda IL-10-1082A/G, B-HDL için duyarlı bir moleküler belirteç değildir.

🔖

Bu Makaleye Atıf Yap

RAHMAN, H. A. A., KHORSHİED, M. M., KHORSHID, O. M. R., MOURAD, H. M. (2018). Association of Interleukin-2-330T/G and Interleukin-10-1082A/G Genetic Polymorphisms with B-Cell Non-Hodgkin Lymphoma in a Cohort of Egyptians. Turkish Journal of Hematology, Cilt: 35 - Sayı: 2, 99–108. https://ajindex.com/articles/412415

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJ. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 2003
  2. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Warzocha K, Coiffier B, Salles G. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 2004
  3. Berglund M, Thunberg U, Roos G, Rosenquist R, Enblad G. The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 2005
  4. Kube D, Hua TD, von Bonin F, Schoof N, Zeynalova S, Klöss M, Gocht D, Potthoff B, Tzvetkov M, Brockmöller J, Löffler M, Pfreundschuh M, Trümper L. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin’s lymphoma: an exploratory study. Clin Cancer Res 2008
  5. Talaat RM, Abdel-Aziza AM, El-Maadawya EA, Abdel-Baryb N. Interleukin 10 gene promoter polymorphism and risk of diffuse large B cell lymphoma (DLBCL). Egyptian Journal of Medical Human Genetics 2014
  6. Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006
  7. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, Whitby D, Chanock S, Rothman N, Armstrong BK. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 2007
  8. Hulkkonen J, Pertovaara M, Antonen J, Lahdenpohja N, Pasternack A, Hurme M. Genetic association between interleukin-10 promoter region polymorphisms and primary Sjögren’s syndrome. Arthritis Rheum 2001
  9. Fayad L, Keating MJ, Reuben JM, O’Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood 2001
  10. Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J, Favrot MC. Serum interleukin-10 in non-Hodgkin’s lymphoma: a prognostic factor. Blood 1993
  11. Rousset F, Garcia E, Defrance T, Péronne C, Vezzio N, Hsu DH, Kastelein R, Moore KW, Banchereau J. In